Get the Stockscreener App
1.49
6.43%
0.09
After Hours:
1.52
0.03
+2.01%
Ovid Therapeutics Inc stock is traded at $1.49, with a volume of 3.03M.
It is up +6.43% in the last 24 hours and down -8.59% over the past month.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
See More
Previous Close:
$1.40
Open:
$1.44
24h Volume:
3.03M
Relative Volume:
1.10
Market Cap:
$106.11M
Revenue:
$391.70K
Net Income/Loss:
$-52.34M
P/E Ratio:
-1.9867
EPS:
-0.75
Net Cash Flow:
$-45.92M
1W Performance:
+14.62%
1M Performance:
-8.59%
6M Performance:
+422.26%
1Y Performance:
+41.90%
1-Day Range:
$1.42
$1.555
1-Week Range:
$1.21
$1.555
52-Week Range:
$0.2425
$2.01
Ovid Therapeutics Inc Stock (OVID) Company Profile
Name
Ovid Therapeutics Inc
Sector
Industry
Phone
212-776-4381
Address
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Compare OVID with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
1.49 | 99.70M | 391.70K | -52.34M | -45.92M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.00 | 108.28B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
761.45 | 79.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.23 | 57.65B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
906.74 | 56.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.93 | 42.39B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-17-25 | Initiated | Leerink Partners | Outperform |
| Oct-09-25 | Initiated | Oppenheimer | Outperform |
| Aug-08-25 | Resumed | B. Riley Securities | Buy |
| Jun-18-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-30-24 | Initiated | B. Riley Securities | Buy |
| Apr-29-24 | Initiated | H.C. Wainwright | Buy |
| Apr-05-24 | Initiated | Wedbush | Outperform |
| Dec-21-23 | Initiated | BTIG Research | Buy |
| Oct-13-23 | Initiated | Oppenheimer | Outperform |
| Apr-20-21 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-03-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-02-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-20 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-04-19 | Initiated | RBC Capital Mkts | Outperform |
| Apr-20-18 | Initiated | Ladenburg Thalmann | Buy |
View All
Ovid Therapeutics Inc Stock (OVID) Latest News
Ovid Therapeutics (OVID): HC Wainwright Raises Price Target to $2.00 | OVID Stock News - GuruFocus
Ovid CEO Meg Alexander Takes The Helm In Time To Harvest Growing Blooms - Citeline News & Insights
Is Ovid Therapeutics Inc. stock overvalued by current metricsJuly 2025 Highlights & Real-Time Market Sentiment Alerts - newser.com
Visual trend scoring systems applied to Ovid Therapeutics Inc.Earnings Risk Summary & Detailed Earnings Play Alerts - newser.com
Will Ovid Therapeutics Inc. (1OT) stock see valuation expansionWeekly Stock Report & Step-by-Step Swing Trade Plans - newser.com
What consensus target says about Ovid Therapeutics Inc. (1OT) stock2025 Growth vs Value & Risk Managed Investment Entry Signals - newser.com
Is Ovid Therapeutics Inc. stock cheap at current valuation2025 Market Outlook & Expert Curated Trade Setups - newser.com
Regression analysis insights on Ovid Therapeutics Inc. performanceDollar Strength & High Yield Equity Trading Tips - newser.com
Ovid Therapeutics Reports Q3 2025 Financial Results - MSN
Combining machine learning predictions for Ovid Therapeutics Inc. - newser.com
Long term hold vs stop loss in Ovid Therapeutics Inc.2025 Short Interest & Community Trade Idea Sharing - newser.com
Historical volatility pattern of Ovid Therapeutics Inc. visualizedWeekly Investment Summary & Free High Accuracy Swing Entry Alerts - newser.com
Leerink Partners Initiates Coverage of Ovid Therapeutics (OVID) with Outperform Recommendation - Nasdaq
This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
OVID: Leerink Partners Initiates Coverage with 'Outperform' Rati - GuruFocus
Leerink Partners Initiates Ovid Therapeutics at Outperform With $5 Price Target - MarketScreener
Can trapped investors hope for a rebound in Ovid Therapeutics Inc.2025 Market Sentiment & Daily Stock Trend Reports - newser.com
Ovid Therapeutics (OVID) Receives Positive Outlook from Analyst - GuruFocus
How Ovid Therapeutics Inc. (1OT) stock correlates with oil marketsMarket Activity Report & Consistent Profit Trading Strategies - newser.com
Published on: 2025-11-16 07:02:40 - newser.com
Price to book ratio of Ovid Therapeutics Inc. – HAM:1OT - TradingView
Published on: 2025-11-14 21:11:45 - newser.com
Is Ovid Therapeutics Inc. (1OT) stock protected from inflationWeekly Profit Summary & Real-Time Buy Signal Notifications - newser.com
Is Ovid Therapeutics Inc. stock oversold or undervaluedPortfolio Update Report & Community Driven Trade Alerts - Fundação Cultural do Pará
Ovid Therapeutics Draws Strong Buy Ratings After Q3 Earnings Update - Finimize
Ovid Therapeutics Inc Stock (OVID) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.13%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):